Compare Neurocrine Biosciences Inc (NBIX) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs BlackRock TCP Capital Corp — how do they compare? Neurocrine Biosciences Inc trades at $142.39 (market cap $14.36B), while BlackRock TCP Capital Corp trades at $3.99 (market cap $337.71M). The key difference: Neurocrine Biosciences Inc is far larger — about 42.5× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 18.88% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and BlackRock TCP Capital Corp for 88 Days on average.
| NBIX | TCPC | |
|---|---|---|
Market Cap | $14.36B | $337.71M |
Volume | 1,237,180 | 436,109 |
Sector | Health | Financials |
52-Week High | $185.50 | $6.20 |
52-Week Low | $123.10 | $3.13 |
Typical Hold Time | 23 Days | 88 Days |
Enterprise Value | $14.37B | $1.09B |
Dividend Yield | — | 18.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
TCPC trades at $4.01, up 1.78% today, with a bullish technical signal from moving averages. The company reported Q2 2026 earnings of $0.22 per share, beating expectations, and announced a $523 million portfolio sale to reduce leverage. However, revenue and net income remain negative, with a net income margin of 118.75% in 2026 indicating significant losses relative to revenue. The stock is trading below book value with a P/B of 0.61.
The outlook is mixed: strategic actions like portfolio sales may improve financial health, but persistent negative earnings and a class action lawsuit pose risks. Analyst sentiment is cautious with a 30.77% buy rating. Investors should weigh the potential for operational turnaround against ongoing profitability challenges and legal overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
